Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "markets"

1033 News Found

Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr
News | August 09, 2025

Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr

Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25


Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr
News | August 08, 2025

Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr

Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025


IOL Chemicals post Q1 FY26 consolidated profit at Rs. 33.93 Cr
News | August 08, 2025

IOL Chemicals post Q1 FY26 consolidated profit at Rs. 33.93 Cr

IOLCP has reported total income of Rs. 559.06 crores during the period ended June 30, 2025


ZIM Laboratories granted marketing authorization for Tamsulosin + Dutasteride capsules in Australia
News | August 08, 2025

ZIM Laboratories granted marketing authorization for Tamsulosin + Dutasteride capsules in Australia

Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men


Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr
News | August 08, 2025

Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr

Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore


Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%
News | August 06, 2025

Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%

The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter


Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr
News | August 06, 2025

Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr

Cenexi reports an EBITDA breakeven for the quarter


Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr
News | August 05, 2025

Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr

The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore


Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr
News | August 02, 2025

Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr

India Formulation sales accounted for 34.2% of total consolidated sales for the quarter


Iberia Pharmaceuticals to open Rs. 70 crore manufacturing unit in India
News | August 02, 2025

Iberia Pharmaceuticals to open Rs. 70 crore manufacturing unit in India

The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements